DYN vs PEPG
DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform. PEPG: PepGen is a clinical-stage biotechnology company developing peptide-enhanced oligonucleotide therapies to treat severe neuromuscular diseases, with a primary focus on Myotonic Dystrophy Type 1.
Side-by-side fundamentals
| Metric | DYN | PEPG | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $16.07 | $2.72 | |
| Market cap | $3.0B | $188M | |
| ROE FY2025, SEC XBRL | -45.9% | -60.8% | DYN higher |
| ROA FY2025, SEC XBRL | -37.6% | -51.6% | DYN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.28 | n/a | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.75 | 1.50 | |
| 1-year return as of 2026-10-21 close | -4.1% | -44.3% | DYN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.